Precede Biosciences Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
48
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$83.5M
- Investors
-
16
Precede Biosciences General Information
Description
Developer of a liquid biopsy platform designed to provide resolution into disease-defining biology from a blood test. The company's platform profiles circulating chromatin and the DNA methylome from plasma, enabling researchers and clinicians to gain insight into the activation of individual genes and pathways in diseased tissues.
Contact Information
Website
www.precede.bioCorporate Office
- 1 Design Center Place
- Suite 19-500
- Boston, MA 02210
- United States
Corporate Office
- 1 Design Center Place
- Suite 19-500
- Boston, MA 02210
- United States
Precede Biosciences Timeline
Precede Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 30-Oct-2025 | $83.5M | Completed | Generating Revenue | ||
| 2. Early Stage VC (Series A) | 13-May-2024 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Precede Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-2 | 9,624,214 | $0.000100 | 8% | $0.7 | $0.7 | 1x | $0.7 | 4.25% |
| Series A-1 | 74,608,314 | $0.000100 | 8% | $0.88 | $0.88 | 1x | $0.88 | 32.95% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Precede Biosciences Comparisons
Industry
Financing
Details
Precede Biosciences Competitors (27)
One of Precede Biosciences’s 27 competitors is BioFluidica, a Venture Capital-Backed company based in Lawrence, KS.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioFluidica | Venture Capital-Backed | Lawrence, KS | ||||
| Exact Sciences | Formerly VC-backed | Madison, WI | ||||
| Araris | Formerly VC-backed | Zurich, Switzerland | ||||
| Menarini Silicon Biosystems | Formerly VC-backed | Castel Maggiore, Italy | ||||
| GRAIL | Formerly VC-backed | Menlo Park, CA |
Precede Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Precede Biosciences Patents
Precede Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026207505-A1 | Circulating tumor fraction estimation models, methods of producing them, and methods of using them | Pending | 28-Mar-2025 | ||
| WO-2026206885-A1 | Methods, kits and systems for determining the er status of cancer and methods for treating cancer based on same | Pending | 24-Mar-2025 | ||
| WO-2026206884-A1 | Methods, kits and systems for determining the her2 status of cancer and methods for treating cancer based on same | Pending | 24-Mar-2025 | ||
| WO-2026206892-A1 | Systems and methods for predicting expression levels of target genes for indications | Pending | 24-Mar-2025 | ||
| WO-2026147976-A2 | Methods, kits and systems for determining ar activity of cancer and methods for treating cancer based on same | Pending | 31-Dec-2024 | C12Q1/6886 |
Precede Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Precede Biosciences Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Bristol-Myers Squibb Foundation | Limited Partner | Minority | ||
| Labcorp Venture Fund | Corporate Venture Capital | Minority | ||
| Mirae Asset Capital | Venture Capital | Minority | ||
| Mirae Asset Capital Life Science | Venture Capital | Minority |
Precede Biosciences FAQs
-
When was Precede Biosciences founded?
Precede Biosciences was founded in 2021.
-
Where is Precede Biosciences headquartered?
Precede Biosciences is headquartered in Boston, MA.
-
What is the size of Precede Biosciences?
Precede Biosciences has 48 total employees.
-
What industry is Precede Biosciences in?
Precede Biosciences’s primary industry is Biotechnology.
-
Is Precede Biosciences a private or public company?
Precede Biosciences is a Private company.
-
What is the current valuation of Precede Biosciences?
The current valuation of Precede Biosciences is .
-
What is Precede Biosciences’s current revenue?
The current revenue for Precede Biosciences is .
-
How much funding has Precede Biosciences raised over time?
Precede Biosciences has raised $132M.
-
Who are Precede Biosciences’s investors?
Alexandria Venture Investments, Bristol-Myers Squibb Foundation, Labcorp Venture Fund, Mirae Asset Capital, and Mirae Asset Capital Life Science are 5 of 16 investors who have invested in Precede Biosciences.
-
Who are Precede Biosciences’s competitors?
BioFluidica, Exact Sciences, Araris, Menarini Silicon Biosystems, and GRAIL are some of the 27 competitors of Precede Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
